Prostate cancer is the most commonly diagnosed cancer in UK men, and London's Royal Marsden, Guy's and St Thomas', and UCLH manage thousands of patients with metastatic castration-resistant prostate cancer (mCRPC). For London patients seeking affordable private or supplementary access, Abiranamo 250mg — the Indian generic of Zytiga — provides identical clinical efficacy at dramatically reduced cost.
Abiranamo contains Abiraterone Acetate, a CYP17A1 inhibitor that blocks androgen synthesis in the testes, adrenal glands, and tumour itself. Combined with low-dose prednisolone, it reduces testosterone to near-castrate levels even after surgical or medical castration. Clinical trials demonstrated extended median overall survival of over 4 months in post-chemotherapy patients and significant benefit in chemotherapy-naive mCRPC.
While NICE-approved Zytiga is available on the NHS for eligible London patients, those in the private sector or not meeting NHS eligibility criteria face costs exceeding £3,500 monthly. Generic Abiranamo from WHO-GMP certified Indian manufacturers delivers the same clinical outcomes at up to 95% lower cost. Visit medshopy.com or WhatsApp +91 82650 41513.
Abiranamo contains Abiraterone Acetate, a CYP17A1 inhibitor that blocks androgen synthesis in the testes, adrenal glands, and tumour itself. Combined with low-dose prednisolone, it reduces testosterone to near-castrate levels even after surgical or medical castration. Clinical trials demonstrated extended median overall survival of over 4 months in post-chemotherapy patients and significant benefit in chemotherapy-naive mCRPC.
While NICE-approved Zytiga is available on the NHS for eligible London patients, those in the private sector or not meeting NHS eligibility criteria face costs exceeding £3,500 monthly. Generic Abiranamo from WHO-GMP certified Indian manufacturers delivers the same clinical outcomes at up to 95% lower cost. Visit medshopy.com or WhatsApp +91 82650 41513.